Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Related Posts

Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer’s disease: A rationale and study design

Leuchter MK, Oughli HA, Durbin KA, Jackson NJ, Elashoff D, Chang TS, Corlier J, Ngo D, Matthews C, Wong D, Fogel BL, Bitan G, Leuchter[...]

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis

White B, Furst DE, Frech TM, Kuwana M, Hummers L, Stevens W, Kafaja S, Lee EB, Distler O, Khanna D, Denton CP, Spiera R; RESOLVE‐1[...]

Subjective Cognitive Decline in COPD – A Cross-Sectional Analysis of the Behavioral Risk Factor Surveillance System

Stellefson ML, Wang MQ, Boyd IM, Flora SM, Campbell OK, Hoth KF, Witt LJ, Kotwal AA, Suen AO, Buhr RG, Iyer AS. Subjective Cognitive Decline[...]